Abstracts tagged "Myopathies"

Abstract Number: 0704 • ACR Convergence 2021
Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
Sonali Narain¹, Ana Valle², Maria-Louise Barilla-Labarca¹ and Galina Marder³, ¹Northwell Health, Great Neck, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: In idiopathic inflammatory myopathies (IIM), SSa/SSb and Ro52 antibodies are frequently reported, especially in association with interstitial lung disease (ILD). However, limited literature exists…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Kazuki Hirano¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Yuji Hosono¹, Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…
Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1086 • ACR Convergence 2020
The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases
Sarah El Chami¹, Christopher Williams¹, Ghaith Noaiseh¹, Amrita Bath¹ and Duaa Jabari¹, ¹The University of Kansas Health System, Kansas city, KS
Background/Purpose: Myositis-specific antibodies (MSA) are thought to be highly specific in patients with idiopathic inflammatory myopathies.[1] However, in clinical practice these antibodies are frequently found…
Abstract Number: 0932 • ACR Convergence 2020
Skeletal Muscle Involvement in Systemic Sclerosis Predisposes to Severe Gastrointestinal Tract and Cardiac Muscle Disease
Reshad Mahmud¹, Lei Zhu², Maureen Laffoon², Thomas Medsger³ and Robyn Domsic⁴, ¹UPMC, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Verona, PA, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Tissues containing muscle cells are affected in systemic sclerosis (SSc) patients in different organ systems: skeletal muscle, cardiac muscle and gastrointestinal (GI) smooth muscle. …
Abstract Number: 1088 • ACR Convergence 2020
Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis
Siamak Moghadam-Kia¹, Chester Oddis², Swamy Venturupalli³, Shalini Mahajan⁴, Daphne Scaramangas Plumley⁵, Dana Ascherman⁶, Nicole Neiman⁷, Faith Onelangsy⁷, Diane Koontz¹, Kim Goldby-Reffner⁷, Sedin Dzanco⁷, Lei Zhu⁶ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Cedars Sinai Medical Center, Los Angeles, ⁴Attune Health, Los Angeles, ⁵Attune Health, Los Angeles, CA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UPMC, Pittsburgh
Background/Purpose: There is a paucity of randomized, controlled clinical trials in myositis. Subject enrollment and retention in clinical trials for this rare, heterogeneous disease has…
Abstract Number: 0933 • ACR Convergence 2020
Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis
Julie Paik¹, Fredrick Wigley², Laura Fayad³, Laura Hummers⁴ and Michael Jacobs¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Joh, Baltimore, MD, ⁴Johns Hopkins Univerisity, Ellicott City, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is underappreciated yet an important manifestation of SSc. While it has been reported that there are distinct histopathologic…
Abstract Number: 1096 • ACR Convergence 2020
Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
Jammie Law¹, Ana Valle², Katherine Mullins³ and Shereen Mahmood⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…
Abstract Number: 0958 • ACR Convergence 2020
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
Rohit Aggarwal¹, Howard Rockette², Swamy Venturupalli³, Galina Marder⁴, Mazen Dimachkie⁵, David Gazeley⁶, Floranne C. Ernste⁷, Leslie Crofford⁸, Siamak Moghadam-Kia⁹, Diane Koontz⁹, Lei Zhu¹ and Chester Oddis¹⁰, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Cedars Sinai Medical Center, Los Angeles, ⁴Northwell, New York, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷Mayo Clinic, Rochester, ⁸Vanderbilt University Medical Center, Nashville, ⁹University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To assess the efficacy and tolerability of tocilizumab (anti-IL-6R, TCZ), in a multi-center, randomized, double blind, placebo-controlled trial in refractory adult dermatomyositis (DM) and…
Abstract Number: 1097 • ACR Convergence 2020
Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies
Hector Culebro¹, Jose Torres-Ruiz², Fabiola Cassiano Quezada¹ and Alfredo Perez Fragoso¹, ¹INCMNSZ, MEXICO, Mexico, ²NIAMS, National Institute of Health, Bethesda
Background/Purpose: Myeloid derived suppressor cells (MDSCs) including their granulocyte (Gr-MDSCs) and monocyte (Mo-MDSCs) subtypes constitute a cellular subset with potent immune regulatory capacity. An augmented…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].